Welcome to our new Vice President of Drug Development and Manufacturing, Dr. Neil Mhaskar! Neil's extensive experience in developing chemistries and processes for traditional as well as difficult-to-formulate drug products will allow to rapidly advance our pipeline!

Today, we announced a licensing agreement with @tamusystem for the exclusive rights to intellectual property around the use of #elesclomol for disorders of mitochondrial copper metabolism, including #Menkesdisease. Learn more: bwnews.pr/3yW1DDt

Today, we announced the close of a $32M extension to our Series A financing led by Nan Fung Life Sciences to support advancement of our diverse neuroscience pipeline, including ongoing execution of ENX-101 and ENX-102 Phase 1 studies. Learn more: bwnews.pr/3jkT1QS

Join us in welcoming our new Associate Director of Clinical Operations, Stephanie Parks! Her 15+ years of experience advancing neuroscience programs through clinical development to approval makes her a perfect fit at Engrail! Learn more here: bit.ly/3AIW8dh

It’s Mental Health Awareness Month! At Engrail, we recognize the importance of raising awareness and fighting the stigma of mental illnesses, and remain focused on developing transformative #neuroscience therapeutics for patients in need. #MHAM

Inspiration comes from many places, and for our Director of Program Management, Rasesh Shah, PhD, it’s being part of our collaborative team at Engrail. Working with a team that puts the patient first drives Rasesh’s innovative work to deliver therapies to address unmet needs.

In honor of #EmployeeAppreciationDay, we would like to extend our sincerest thank you to our team. We are grateful for your hard work and dedication to developing transformative medicines for patients with life-limiting diseases of the nervous system.

For our employees, #science is a passion, even for those of us without scientific training. Hear from our Sr. Director, Commercial Strategy, on how she got started in the life sciences industry and her role at Engrail.

Here at Engrail, #neuroscience is our passion. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Learn more: engrail.com

Today, we announced the acquisition of NeuroCycle Therapeutics, strengthening our pipeline in the #GABA-A space. We expect 2021 to be a busy year as we consider additional transactions to expand our portfolio. Learn more: bwnews.pr/3rc9p8I

We are so excited to have such a talented neurobiologist join the Engrail Team. Welcome Krishna!!

Jordi joined Engrail in December 2019 as Sr. Director, Neurobiology and has demonstrated tremendous scientific leadership, influencing our direction significantly. We are thrilled to participate in the success of one of our own. Congratulations Jordi!

We are excited to announce the addition of Dr. Kimberly Vanover and Dr. Eve Taylor to the Engrail team and Dr. Tony Ho to the Engrail Board! businesswire.com/news/home/2…

Excited to announce our recent $32M Series A Financing! businesswire.com/news/home/2…